Fate Therapeutics, Inc.
- FATE
- NASDAQ
- Biotechnology
- Cell Immunotherapies
- iPSC Platform
$2.06
Today +10.75%Quote Oct 20, 2026, 08:00 PM UTC
−18.58%over the last month
Max drawdown −30.6%From 1-month high −20.2%3 months −20.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Fate Therapeutics
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
161
Market value
$240.1M
Quote Oct 20
Floor
$2.05
0.3% below price
Resistance
$2.25
9.3% above price
Price vs analyst targets
31 analysts
Lowest target
$3.50Highest target
$8.00
$3.50Highest target
$8.00
- Price $2.06
- Average target $5.63
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 173% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about FATEPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free